Abstract
This double- blind study assesses the therapeutic efficacy and the safety of oral treatment with phosphatidylserine (BC- PS) vs placebo (300 mg/day for 6 months) in a group of geriatric patients with cognitive impairment. A total of 494 elderly patients (age between 65 and 93 years), with moderate to severe cognitive decline, according to the Mini Mental State Examination and Global DeteriorationScale, were recruited in 23 Geriatric or General Medicine Units in Northeastern Italy. Sixty- nine patients dropped out within the 6- month trial period. Patients were examined just before starting therapy, and 3 and 6 months thereafter. The efficacy of treatment compared to placebo was measured on the basis of changes occurring in behavior and cognitive performance using the Plutchik Geriatric Rating Scale and the Buschke Selective Reminding Test. Statistically significant improvements in the phosphatidylserine- treated group compared to placebo were observed both in terms of behavioral and cognitive parameters. In addition, clinical evaluation and laboratory tests demonstrated that BC- PS was well tolerated. These results are clinically important since the patients were representative of the geriatric population commonly met in clinical practice. (Aging Clin. Exp. Res. 5: 123- 133, 1993).
This is a preview of subscription content, access via your institution.
References
- 1.
Greene J.G., Smith R., Gardiner M., Timbury G.C.: Measuring behavioural disturbance of elderly demented patients in the community and its effects on relatives: a factor analytic study. Age Ageing 11: 121–126, 1982.
- 2.
Folstein M.F., Anthony J.C., Parhad I., Duffy B., Gruenberg E.M.: The meaning of cognitive impairment in the elderly. J. Am. Geriatr. Soc. 33: 228–235, 1985.
- 3.
Katzman R.: Alzheimer’s disease. N. Engl. J. Med. 314: 964–973, 1986.
- 4.
Svennerholm L., Bostrom K., Heiander C.G., Jungbjer B.: Membrane lipids in the aging human brain. J. Neurochem. 56: 2051–2059, 1991.
- 5.
Schroeder F.: Role of membrane lipid asymmetry in aging. Neurobiol. Aging 5: 323–333, 1984.
- 6.
Rapoport S.I., London E.D.: Brain metabolism during aging of the rat and dog. Implications for brain function in man during aging and dementia. In: Terry R.D., Bolis C.G., Toffano G. (Eds.), Neural Aging and its implications in human neurological pathology. Raven Press, New York, 1982, pp. 79–88.
- 7.
Hirata F., Axelrod J.: Phospholipid methylation and biological signal transmission. Science 209: 1082–1090, 1980.
- 8.
DeKosky S.T., Scheff S.W.: Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann. Neurol. 27: 457–464, 1990.
- 9.
Feinstein A.R.: An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann. Intern. Med. 99: 544–550, 1983.
- 10.
Toffano G., Bruni A.: Pharmacological properties of phospholipid liposomes. Pharmacol. Res. Commun. 12: 829–845, 1980.
- 11.
Calderini G., Bellini F., Bonetti A.C., Galbiati E., Guidolin D., Milan F., Nunzi M.G., Rubini R., Zanotti A., Toffano G.: Pharmacological properties of phosphatidylserine in the ageing brain. Clin. Trials J. 24: 9–17, 1987.
- 12.
Toffano G., Leon A., Mazzari S., Savoini G., Teolato S., Orlando P.: Modification of noradrenergic hypothalamic system in rat injected with phosphatidylserine liposomes. Life Sci. 23: 1093–1102, 1987.
- 13.
Mazzari S., Battistella A.: Phosphatidylserine effects on dopamine release from striatum synaptosomes. In: Di Benedetta C., Balazs R., Gombos G., Porcellati G. (Eds.), Multidisciplinary approach to brain development. North-Holland/Elsevier, Amsterdam, 1980, pp. 569–570.
- 14.
Vannucchi M.G., Pepeu G.: Effect of phosphatidylserine on acetylcholine release and content in cortical slices from aging rats. Neurobiol. Aging 8: 403–407, 1987.
- 15.
Casamenti F., Scali C., Pepeu G.: Phosphatidylserine reverses the age-dependent decrease in cortical acetylcholine release: a microdialysis study. Eur. J. Pharmacol. 194: 11–16, 1991.
- 16.
Nunzi M.G., Milan F., Guidolin D., Toffano G.: Dendritic spine loss in hippocampus of aged rats. Effect of brain phosphatidylserine administration. Neurobiol. Aging 8: 501–551, 1987.
- 17.
Guidolin D., Milan F., Polato P., Nunzi M.G., Toffano G.: Phosphatidylserine treatment prevents age-induced structural alterations in the rat septo-hippocampal system. In: Bazan N.G., Horrocks L.A., Toffano G. (Eds.), Phospholipid in the nervous system: biochemical and molecular pathology. Liviana Press, Padova, 1989, pp. 183–193.
- 18.
Corwin J., Dean R.L. III, Bartus R.T., Rotrosen J., Watkins D.L.: Behavioral effects of phosphatidylserine in the aged Fischer 344 rat: amelioration of passive avoidance deficits without changes in psychomotor task performance. Neurobiol. Aging 6: 11–15, 1985.
- 19.
Drago F., Canonico P.L., Scapagnini U.: Behavioral effects of phosphatidylserine in aged rats. Neurobiol. Aging 2: 209–213, 1981.
- 20.
Zanotti A., Valzelli L., Toffano G.: Chronic phosphatidylserine treatment improves spatial memory and passive avoidance in aged rats. Psychopharmacology 99: 316–321, 1989.
- 21.
Amaducci L., Crook T.H., Lippi A.: Use of phosphatidylserine in Alzheimer’s Disease. Ann. N.Y. Acad. Sci. 640: 245–249, 1991.
- 22.
Monteleone P., Beinat L., Tanzillo C., Maj M., Kemali D.: Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans. Neuroendocrinology 52: 243–248, 1990.
- 23.
Monteleone P., Maj M., Beinat L., Natale M., Kemali D.: Blunting by chronic phosphatidylserine of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur. J. Clin. Pharmacol. 41: 385–388, 1992.
- 24.
Rosadini G., Sannita W.G., Nobili F., Cenacchi T.: Phosphatidylserine: quantitative EEG effects in healthy volunteers. Neuropsychobiology 24: 42–48, 1991.
- 25.
Klinkhammer P., Szelies B., Heiss W.D.: Effect of phosphatidylserine on cerebral glucose metabolism in Alzheimer’s disease. Dementia 1: 197–201, 1990.
- 26.
Palmieri G., Palmieri R., Inzoli M.R., Lomabardi G., Sottini C., Tavolato B., Giometto B.: Double-blind controlled trial of phosphatidylserine in patients with senile mental deterioration. Clin. Trials J. 24: 73–83, 1987.
- 27.
Villardita C., Grioli S., Salmeri G., Nicoletti F., Pennisi G.: Multicentre clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration. Clin. Trials J. 24: 84–93, 1987.
- 28.
Maggioni M., Picotti G.B., Bondiolotti G.P., Panerai A., Cenacchi T., Nobile P., Brambilla F.: Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Acta Psychiatr. Scand. 81: 265–270, 1990.
- 29.
Crook T.H., Tinklenberg J., Yesavage J., Petrie W., Nunzi M.G., Massari C.D.: Effects of phosphatidylserine in age-associated memory impairment. Neurology 41: 644–649, 1991.
- 30.
Delwaide P.J., Gyselynck-Mambourg A.M., Hurlet A., Ylieff M.: Double-blind randomized controlled study of phosphatidylserine in senile demented patients. Acta Neurol. Scand. 73: 136–140, 1986.
- 31.
Amaducci L. and the SMID Group: Phosphatidylserine in the treatment of Alzheimer’s disease: results of a multicenter study. Psychopharmacol. Bull. 24: 130–134, 1988.
- 32.
Folstein M.F., Folstein S.E., McHugh P.R.: “Mini Mental State”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12: 189–198, 1975.
- 33.
Reisberg B.: The brief cognitive rating scale and Global Deterioration Scale. In: Crook T., Ferris S., Bartus R. (Eds.), Assessment in Geriatric Psychopharmacology. Mark Powley Associates, New Canaan, Connecticut, 1983, pp. 19–28.
- 34.
Reisberg B., Ferris S.H., Crook T.: Guidelines for drug trials in the treatment of age-associated cognitive decline and Alzheimer’s disease. Drug Inf. J. 19: 405–420, 1985.
- 35.
Wells C.E.: Pseudodementia. Am. J. Psychiatry 136: 895–900, 1979.
- 36.
Blessed G., Tomlinson B.E., Roth M.: The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br. J. Psychiatry 114: 797–811, 1968.
- 37.
Hamilton M.: A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23: 56–62, 1960.
- 38.
Hamilton M.: Rating depressive patients. J. Clin. Psychiatry 41: 21–24, 1980.
- 39.
Plutchik R., Conte H., Lieberman M., Bakur M., Grossman J., Lehrman N.: Reliability and validity of a scale for assessing the functioning of geriatric patients. J. Am. Geriatr. Soc. 18: 491–500, 1970.
- 40.
Buschke H., Fuld P.A.: Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 24: 1019–1025, 1974.
- 41.
Smith J.M., Bright B., McCloskey J.: Factor analytic composition of the Geriatric Rating Scale (GRS). J. Gerontol. 32: 58–62, 1977.
- 42.
Muramoto O.: Selective reminding in normal and demented aged people: auditory verbal versus visual spatial task. Cortex 20: 461–478, 1984.
- 43.
Bartolini V., Tagliavini C., Zampolli A.: Lessico di Frequenza della Lingua Italiana Contemporanea. Garzanti, Milano, 1972.
- 44.
Bertoldin T., Farina C., Crepaldi G.: Memory function, cognitive status and aging: a study employing MMSE and Selective Reminding Technique. The Third Congress of the International Psychogeriatric Association, Chicago, Illinois, U.S.A., 1987, pp. 97–98, (Abstract).
- 45.
Hachinski V., Iliff L., Du Boulay G., Phil M., Zilhka E, McAllister L., Marshall J.: Cerebral blood flow in dementia. Arch. Neurol 32: 632–637, 1975.
- 46.
Fleiss J.L.: Analysis of data from Multicentric Trials. Controlled Clin. Trials 7: 267–275, 1986.
- 47.
Larson E.B., Reifler B.V., Sumi S.M., Canfield C.G., Chinn N.M.: Diagnostic evaluation of 200 elderly outpatients with suspected dementia. J. Gerontol. 40: 536–543, 1985.
- 48.
Parkin A.J., Walter B.M.: Aging, short-term memory, and frontal dysfunction. Psychobiology 19: 175–179, 1991.
Author information
Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cenacchi, T., Bertoldin, T., Farina, C. et al. Cognitive decline in the elderly: A double- blind, placebo- controlled multicenter study on efficacy of phosphatidylserine administration. Aging Clin Exp Res 5, 123–133 (1993). https://doi.org/10.1007/BF03324139
Received:
Accepted:
Published:
Issue Date:
Keywords
- Cognitive decline
- elderly
- phosphatidylserine